Journal profile · Medicine, Research & Experimental
Current Molecular Medicine
ISSN 1566-5240 · eISSN 1875-5666 · Bentham Science Publishers B.V. · NETHERLANDS · Bimonthly · Founded 2001
Current Molecular Medicine: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.77; hybrid open access; median 102 days to acceptance (60 articles, last 24 months); community-reported acceptance: moderate; 119 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Current Molecular Medicine is published by Bentham Science Publishers B.V. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are MicroRNA in disease regulation, Cancer, Hypoxia, and Metabolism and Cancer-related molecular mechanisms research, together about 20.2% of its articles. Its main subfields are Cancer Research and Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
Current Molecular Medicine is an interdisciplinary journal focused on providing the readership with current and comprehensive reviews/ mini-reviews, original research articles, short communications/letters and drug clinical trial studies on fundamental molecular mechanisms of disease pathogenesis, the development of molecular-diagnosis and/or novel approaches to rational treatment. The reviews should be of significant interest to basic researchers and clinical investigators in molecular medicine. Periodically the journal invites guest editors to devote an issue on a basic research area that shows promise to advance our understanding of the molecular mechanism(s) of a disease or has potential for clinical applications.
Source: LetPub
Research area (LetPub): Medicine, Research & Experimental
Main research topics OpenAlex counts of recent articles; shares are approximate
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology8.7%
- Cancer, Hypoxia, and MetabolismBiochemistry, Genetics and Molecular Biology6%
- Cancer-related molecular mechanisms researchBiochemistry, Genetics and Molecular Biology5.5%
- Mitochondrial Function and PathologyBiochemistry, Genetics and Molecular Biology5%
- Circular RNAs in diseasesBiochemistry, Genetics and Molecular Biology4.9%
- Immunotherapy and Immune ResponsesImmunology and Microbiology4.6%
- Endoplasmic Reticulum Stress and DiseaseBiochemistry, Genetics and Molecular Biology4.5%
- Immune Cell Function and InteractionImmunology and Microbiology4.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Medicine, Research & Experimental | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Medicine, Research & Experimental | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Medicine, Research & Experimental | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.77LetPub ·
- CiteScore 2026-06
- 4.9LetPub ·
- SJR 2026-06
- 0.65LetPub ·
- SNIP 2026-06
- 0.67LetPub ·
- h-index
- 93LetPub ·
- h-index
- 132OpenAlex ·
- i10-index
- 1,451OpenAlex ·
- 2-year mean citedness
- 1.7OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 6.38%LetPub ·
Volume
- Articles per year
- 125LetPub ·
Articles by year OpenAlex count · 2,537 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 87 | 4 | 11 |
| 2025 | 119 | 14 | 174 |
| 2024 | 81 | 6 | 303 |
| 2023 | 131 | 9 | 858 |
| 2022 | 114 | 4 | 1,056 |
| 2021 | 123 | 9 | 1,461 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
102 daysMedian, submission to acceptance · P25–P75 80 days – 129 days
- Acceptance to online
- median 202 days (60 articles)
- Submission to online
- median 311 days
- Sample
- 60 articles with submission and acceptance dates (323 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 4–8 weeksLetPub ·
- Average acceptance (community reports)
- ModerateLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Bentham Science Publishers B.V.
- Country or region
- NETHERLANDS
- Language
- English
- Frequency
- Bimonthly
- Founded
- 2001
- ISSN
- 1566-5240
- Electronic ISSN
- 1875-5666
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Current Molecular Medicine
What CAS zone is Current Molecular Medicine in?
In the 2025 upgraded edition of the CAS Journal Ranking, Current Molecular Medicine is in Zone 4 of Medicine, and in Zone 4 of the minor category Medicine, Research & Experimental. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Current Molecular Medicine?
The latest impact factor listed by LetPub is 2.77; CiteScore 4.9, h-index 132.
How long does peer review take at Current Molecular Medicine?
Based on the dates recorded on 60 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 102 days (interquartile range 80–129 days); authors report an average review time of 4–8 weeks; the community-reported acceptance is “Moderate”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Current Molecular Medicine?
According to LetPub and DOAJ records, Current Molecular Medicine is indexed in SCIE and Scopus.
Is Current Molecular Medicine open access, and what is the APC?
Current Molecular Medicine is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .